All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2022-02-08T16:08:56.000Z

Is sorafenib the new standard maintenance treatment for FLT3 mutant AML?

By Mark Maitland
Featured
Yi-Bin Chen
Feb 8, 2022
Share:

Bookmark this article

During The 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021), the AML Hub was pleased to speak with Yi-Bin Chen, Massachusetts General hospital, Boston, US. We asked, Is sorafenib the new standard maintenance treatment for FLT3 mutant AML?

Is sorafenib the new standard maintenance treatment for FLT3 mutant AML?

Chen begins by highlighting advances and describing sorafenib as the new standard of care after allo-SCT in FLT3 mutated AML. He outlines the benefits of allo-HSCT as a consolidation therapy as well as studies on maintenance therapies after transplant using FLT3 inhibitors. Finally, he discusses differences in the availability and toxicity of these agents e.g. midostatorin and gilteritinib.

 

More about...
AML-related mutationsCOSTEM 2021MidostaurinSorafenib

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 2 days left ...

Related articles

Add bookmark

2022 ELN recommendations for the management of AML in adults

A summary of the updated guidelines for the management of AML, from the same publication in Blood, by Döhner et al. on behalf of the ELN.

Sep 28, 2022
Add bookmark

2022 ELN recommendations for the management of AML in adults

A summary of the updated guidelines for the management of AML, from the same publication in Blood, by Döhner et al. on behalf of the ELN.

Sep 28, 2022
Add bookmark

Triplet combination of HMA, FLT3 inhibitors, and venetoclax in FLT3-mutated newly diagnosed AML

This study suggests that in older/unfit adult patients with newly diagnosed AML the triplet combination of HMA, FLT3 inhibitor, and venetoclax is...

Jun 15, 2022
Add bookmark

Triplet combination of HMA, FLT3 inhibitors, and venetoclax in FLT3-mutated newly diagnosed AML

This study suggests that in older/unfit adult patients with newly diagnosed AML the triplet combination...

Jun 15, 2022

Newsletter

Subscribe to get the best content related to AML delivered to your inbox